AbbVie 2014 Annual Report Download - page 41

Download and view the complete annual report

Please find page 41 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

13NOV201221352027
R&D efforts will continue to focus a significant portion of expenditures on compounds for immunology,
virology/liver disease, oncology, renal disease, neurological diseases and women’s health. AbbVie’s scientists
work to advance a pipeline of specialty molecules that demonstrate strong clinical performance for patients
and economic value for patients and their healthcare systems. Current R&D projects are described in the
‘‘Research and Development’’ section below. Abbvie will also continue to augment its pipeline through
concerted focus on strategic licensing, acquisition and partnering activity in 2015.
Research and Development
Research and innovation continues to be a key strategic priority for AbbVie. AbbVie’s long-term success
depends to a great extent on its ability to continue to discover and develop innovative pharmaceutical
products and acquire or collaborate on compounds currently in development at other biotechnology or
pharmaceutical companies.
AbbVie’s pipeline includes more than 40 compounds or indications in clinical development individually
or under collaboration or license agreements. Of these programs, approximately 13 are in Phase 3
development or in registration. AbbVie expects multiple Phase 2 programs to transition into Phase 3
programs during 2015. R&D is focused on therapeutic areas that include immunology, virology/liver disease,
oncology, renal disease, neurological diseases, and women’s health, among others.
Immunology
HUMIRA is approved to treat the following autoimmune diseases in the United States, Canada, and
Mexico (collectively, North America), and in the European Union:
Condition Principal Markets
Rheumatoid arthritis (moderate to severe) North America, European Union
Psoriatic arthritis North America, European Union
Ankylosing spondylitis North America, European Union
Crohn’s disease (moderate to severe) North America, European Union
Plaque psoriasis (moderate to severe) North America, European Union
Juvenile idiopathic arthritis North America, European Union
Ulcerative colitis (moderate to severe) United States, European Union
Axial spondyloarthropathy United States, European Union
Pediatric Crohn’s disease (severe) United States, European Union
Pediatric enthesitis-related arthritis European Union
AbbVie continues to dedicate R&D efforts to expanding indications for HUMIRA, including in the fields
of gastroenterology, dermatology and ophthalmology. Phase 3 trials are ongoing in preparation for
regulatory applications of HUMIRA for uveitis in the United States and the European Union. A regulatory
application for hidradenitis suppurativa has been filed in the United States and the European Union.
AbbVie also has a number of next-generation programs underway to address immune-mediated
conditions, including the following:
• AbbVie’s studies of dual variable domain immunoglobulin (DVD-Ig) technology, which represents an
approach that can target multiple disease-causing antigens with a single biologic agent, continue to
progress. This proprietary technology could lead to next-generation biologic treatments for complex
conditions such as cancer or rheumatoid arthritis, where multiple pathways are involved in the
disease. ABT-122, a DVD directed against IL-17 and TNF, is currently in Phase 2 investigation in RA,
and ABT-981, a DVD targeting IL-1 alpha and beta, is being studied in osteoarthritis in an ongoing
Phase 2 program.
2014 Form 10-K 35